A team led by Prof. Wuran Wei from West China Hospital of Sichuan University and Dr. Dechao Feng from the Division of Surgery ...

The data to be presented encompasses five of the company’s novel drug candidates: BCR-ABL tyrosine kinase inhibitor olverembatinib (HQP1351), Bcl-2 inhibitor lisaftoclax (APG-2575), FAK/ALK/ROS1 ...

Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch (UTMB), Galveston, Texas 77555, United States ...

An MDM2 inhibitor, an E3 ligase that regulates p53, is another key target in DDL. Although the phase III MANTRA trial of milademetan, an MDM2 inhibitor, failed to meet its primary endpoint, ...

Comprehensive genomic studies of ACC have revealed recurrent mutations in critical pathways, including Wnt/β-catenin (ZNRF3, CTNNB1), p53-driven apoptosis and cell cycle regulation (CDKN2A, CDK4, RB1, ...